Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease

Canadian Journal of Gastroenterology

Volumn 13, Issue 2, 1999, Pages 159-162

  Kirkpatrick, Andrew W ^a   Bookman, Arthur A ^b   Habal, Flavio ^c  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Aminosalicylic acids; Drug toxicity; Inflammatory bowel disease; Lupus like syndrome

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTINUCLEAR ANTIBODY; MESALAZINE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0032953978     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/361431     Document Type: Article

References (24)

1. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987;317:1625-9.
2. Sharma VK. Safety profile of the new 5-ASA based compounds. Can J Gastroenterol 1990;4:443-5.
3. de Franchis R, Vecchi M, Carpinelli L, Meucci G, Torgano G. Comparison of the efficacy and safety of sulphasalazine and mesalazines in the maintenance treatment of ulcerative colitis - a meta-analysis. Eur J Gastroenterol Hepatol 1993;5:505-10.
4. Griffiths ID, Kane SP. Sulphasalazine-induced lupus syndrome in ulcerative colitis. Br Med J 1977;ii:1188-9.
5. Carr-Locke DL. Sulfasalazine-induced lupus syndrome in a patient with Crohn's Disease. Am J Gastroenterol 1982;77:614-6.
6. Price EJ, Venables PJW. Drug-induced lupus. Drug Saf 1995;12:283-90.
7. Bray VJ, West SG, Schulz KT, Boumpas DT, Rubin RL. Antihistone antibody profile in sulfasalazine induced lupus. J Rheumatol 1994;21:2157-8.
8. Habal FM, Hui G, Greenberg R. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993;105:1057-60.
9. Lim AG, Hine KR. Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine. BMJ 1994;308:113.
10. Welte T, Hamm H, Fabel H. Mesalazine alveolitis. Lancet 1991;338:1273.
11. Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology 1992;103:1925-7.
12. Dent MT, Ganapathy S, Holdworth CD, Chaanner KC. Mesalazine induced lupus-like syndrome. BMJ 1992;305:159.
13. Gunnarson I, Pettersson E, Lindblad S, Ringertz B. Olsalazine-induced lupus syndrome. Scand J Rheumatol 1997;26:65-6.
14. Stevens MB. Drug induced lupus. Hosp Pract 1992;27:27-36.
15. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am 1994;20:61-86.
16. Hahn H. Systemic lupus erythematosus. In: Isselacher KJ, Raunwald E, Wilson JD, Matin J, Fauci AS, Kasper DL, eds. Principles of Internal Medicine, 13th edn. New York: McGraw-Hill, 1993:1643-8.
17. Cush JJ, Goldings EA. Southwestern internal medicine conference: drug-induced lupus: clinical spectrum and pathogenesis. Am J Med Sci 1985;290:36-45.
18. Hess EV. Role of drugs and environmental agents in lupus syndromes. Curr Opin Rheumatol 1992;4:688-92.
19. Clementz GL, Dolin BJ. Sulfasalazine-induced lupus erythematosus. Am J Med 1988;84:535-8.
20. Wollheim FA. Enteropathic arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: WB Saunders, 1993:985-94.
21. Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children: relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci 1986;31:492-7.
22. Wright V, Watkinson G. The arthritis of ulcerative colitis. BMJ 1965;ii:670-5.
23. Scheurlen M, Mork H, Weber P. Hypereosinophilic syndrome resembling chronic inflammatory bowel disease with primary sclerosing cholangitis. J Clin Gastroenterol 1992;14:59-63.
24. Riisager PM, Oxon BA. Eosinophil leucocytes in ulcerative colitis. Lancet 1959;ii:1008-9.